Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intuitive Surgical names Ed Rozynski as head of government affairs program

This article was originally published in Clinica

Executive Summary

Global medical device industry strategist Ed Rozynski has joined the maker of the da Vinci laparoscopic robotic surgery device, Intuitive Surgical, where he will launch the Sunnyvale, California firm’s government affairs program. In his new role Mr Rozynski will draw on recent experiences in a senior international post at the US Medical Device Manufacturers Association ( MDMA), where he advised US device companies on how to succeed in the emerging global device markets, among other things. Before that industry association role (his second, having worked in a senior international post at AdvaMed in the 13 years to 2002), Mr Rozynski was global government affairs program leader at orthopedics manufacturer Stryker. Intuitive’s da Vinci robotics tools are used in urology, gynecology, cardiothoracic, general surgery and transoral robotic surgery, among other fields.

Topics

UsernamePublicRestriction

Register

MT101105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel